

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: RFA2/22 - Risk Factors for Atherosclerosis

Deadline: 14.10.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(111) Cholesterol</b>					40							40	39	98%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		7,09	0,23	3,2	40	CVP	7,033	8%	6,44	7,56	40	40	100%	
(1) Enzyme method CHOD-PAP		7,09	0,23	3,2	40	0					40			
<b>Sample B</b>		3,38	0,12	3,5	40	CVP	3,35	8%	3,08	3,62	40	39	98%	
(1) Enzyme method CHOD-PAP		3,38	0,12	3,5	40	0					40			
<b>(112) Triacylglycerols</b>					39						39	38	97%	
— Samples and groups	[mmol/L]													
<b>Sample A</b>		2,15	0,058	2,7	39	CVP	2,16	15%	1,83	2,49	39	39	100%	
(1) Photometric enzyme (GPO-PAP)		2,15	0,059	2,7	36	0					36			
Other					3	0					3			
<b>Sample B</b>		1,04	0,045	4,3	39	CVP	1,04	15%	0,884	1,2	39	38	97%	
(1) Photometric enzyme (GPO-PAP)		1,04	0,047	4,5	36	0					36			
Other					3	0					3			
<b>(113) Cholesterol HDL</b>					40						40	39	98%	
— Samples and groups	[mmol/L]													
<b>Sample A</b>		1,88	0,076	4,1	40	CVP	1,89	15%	1,6	2,18	40	40	100%	
(2) Direct determination		1,88	0,074	3,9	39	0					39			
Other					1	0					1			
<b>Sample B</b>		0,919	0,05	5,4	40	CVP	0,92	15%	0,782	1,06	40	39	98%	
(2) Direct determination		0,921	0,048	5,2	39	0					39			
Other					1	0					1			
<b>(114) Apolipoprotein AI</b>					12						12	12	100%	
— Samples and groups	[g/L]													
<b>Sample A</b>		2,09	0,17	8,2	12	CVP	2,14	21%	1,69	2,59	12	12	100%	
(2) Immunoturbidimetry		2,10	0,13	6,3	10	0					10			
Other					2	0					2			
<b>Sample B</b>		1,02	0,063	6,2	12	CVP	1,04	21%	0,821	1,26	12	12	100%	
(2) Immunoturbidimetry		1,02	0,055	5,4	10	0					10			
Other					2	0					2			
<b>(115) Apolipoprotein B</b>					13						13	13	100%	
— Samples and groups	[g/L]													
<b>Sample A</b>		1,29	0,079	6,1	13	CVP	1,31	18%	1,07	1,55	13	13	100%	
(2) Immunoturbidimetry		1,29	0,087	6,7	11	0					11			
Other					2	0					2			
<b>Sample B</b>		0,655	0,063	9,7	13	CVP	0,642	18%	0,526	0,758	13	13	100%	
(2) Immunoturbidimetry		0,650	0,065	10	11	0					11			
Other					2	0					2			
<b>(116) Cholesterol LDL (calculation)</b>					10						10	10	100%	
— Samples and groups	[mmol/L]													
<b>Sample A</b>		4,25	0,23	5,4	10	CVP	4,15	15%	3,52	4,78	10	10	100%	
(0) Not specified		4,25	0,23	5,4	10	0					10			
<b>Sample B</b>		2,00	0,13	6,6	10	CVP	1,97	15%	1,67	2,27	10	10	100%	
(0) Not specified		2,00	0,13	6,6	10	0					10			
<b>(118) Cholesterol LDL (direct determ.)</b>					32						32	32	100%	
— Samples and groups	[mmol/L]													
<b>Sample A</b>		4,23	0,39	9,2	32	CVP	4,27	15%	3,62	4,92	32	32	100%	
(1) Removed non-LDL (peroxidase)		4,24	0,47	11	7	0					7			
(2) Removed non-LDL (catalase and perox.)		4,38	0,29	6,6	16	0					16			
(3) Selective determination		4,13	0,53	13	6	0					6			
Other					3	0					3			
<b>Sample B</b>		2,04	0,15	7,1	32	CVP	2,04	15%	1,73	2,35	32	32	100%	
(1) Removed non-LDL (peroxidase)		2,03	0,16	8,0	7	0					7			
(2) Removed non-LDL (catalase and perox.)		2,08	0,10	4,9	16	0					16			
(3) Selective determination		2,05	0,26	13	6	0					6			

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: RFA2/22 - Risk Factors for Atherosclerosis

Deadline: 14.10.2022

Test	[unit]						Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(118) Cholesterol LDL (direct determ.)</b>	[mmol/L]				32								32	32	100%
Samples and groups															
<b>Sample B</b>		2,04	0,15	7,1	32	CVP	2,04	0,027	15%	1,73	2,35	32	32	100%	
Other					3	0						3			
						3x 99									
<b>(117) Lipoprotein (a) [g/L]</b>	[g/L]				7							7	7	100%	
Samples and groups															
<b>Sample A</b>		0,301	0,044	15	7	CVP	0,322	0,011	32%	0,218	0,426	7	7	100%	
(2) Immunoturbidimetry		0,307	0,034	11	6	0						6			
Other					1	0						1			
						1x 3									
<b>Sample B</b>		0,156	0,036	23	7	CVP	0,181	,0072	32%	0,123	0,239	7	7	100%	
(2) Immunoturbidimetry		0,164	0,024	14	6	0						6			
Other					1	0						1			
						1x 3									
<b>(119) Lipoprotein (a) [nmol/L]</b>	[nmol/L]				5							5	3	60%	
Samples and groups															
<b>Sample A</b>		57,2	7,4	13	5	CVP	63,4	1,7	20%	50,7	76,1	5	4	80%	
(2) Immunoturbidimetry		57,2	7,4	13	5	0						5			
<b>Sample B</b>		28,0	6,2	22	5	CVP	32,1	1,2	20%	25,6	38,6	5	3	60%	
(2) Immunoturbidimetry		28,0	6,2	22	5	0						5			
st_kn_p															
End of report												Printed: 23.10.2022			